Compare Workiva Inc (WK) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Workiva Inc vs Zoetis Inc — how do they compare? Workiva Inc trades at $72.76 (market cap $3.96B), while Zoetis Inc trades at $73.83 (market cap $30.29B). The key difference: Zoetis Inc is far larger — about 7.6× Workiva Inc's market cap, and Zoetis Inc pays a 2.89% dividend while Workiva Inc pays none. Which is the better fit depends on your goals.
| WK | ZTS | |
|---|---|---|
Market Cap | $3.96B | $30.29B |
Sector | Technology | Health |
52-Week High | $93.31 | $150.61 |
52-Week Low | $44.31 | $71.91 |
Enterprise Value | $3.94B | $37.86B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Workiva (WK) trades at $73.71, down 3.71% today but showing strong fundamental momentum with three consecutive quarterly earnings beats. The stock maintains bullish technical positioning near key support at $72 with an overall bullish signal from moving averages. Recent Q2 2026 results showed 19% revenue growth to $255 million, exceeding guidance, while the company continues to expand its AI capabilities with new product launches.
The outlook remains positive with 89% analyst buy ratings and an $82.50 consensus target offering 12% upside. However, elevated valuation multiples (P/E 86.6) and negative 2025 net income present risks. Key catalysts include continued AI adoption and Q3 earnings, while competition and execution risks warrant monitoring.
Zoetis (ZTS) trades at $73.6, down 2.92% on the day, near its 52-week low amid bearish technical signals. The stock shows strong fundamentals with a P/E of 12, net margin of 27.69%, and consistent earnings beats, but faces headwinds from weak U.S. companion animal sales and reduced 2026 guidance. Recent news includes an FDA emergency use authorization for Simparica Trio and participation in healthcare conferences.
The outlook is mixed: valuation appears attractive with a consensus price target of $93.40, but near-term risks include competitive pressures and soft pet health demand. Long-term investors may find value in its profitability and market dominance, though volatility persists from sector challenges and investor sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
